We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
CVS Health
CVS
$137B
| $144M | 0.34% |
1,830,137
+19,759
| +1% | +$1.58M |
|
52
Booking.com
BKNG
$145B
| $143M | 0.33% |
2,013,475
+26,625
| +1% | +$1.76M |
|
53
Texas Instruments
TXN
$255B
| $141M | 0.33% |
1,753,135
+15,099
| +0.9% | +$1.17M |
|
54
Starbucks
SBUX
$118B
| $139M | 0.33% |
2,383,016
+13,988
| +0.6% | +$792K |
|
55
Bristol-Myers Squibb
BMY
$128B
| $139M | 0.32% |
2,549,646
+33,766
| +1% | +$1.85M |
|
|
56
Abbott
ABT
$182B
| $134M | 0.31% |
3,012,634
+505,352
| +20% | +$21.8M |
|
57
Eli Lilly
LLY
$1.07T
| $133M | 0.31% |
1,578,991
+79,286
| +5% | +$6.35M |
|
58
Broadcom
AVGO
$1.82T
| $131M | 0.31% |
5,978,290
+72,170
| +1% | +$1.49M |
|
59
Costco
COST
$422B
| $129M | 0.3% |
770,297
+22,405
| +3% | +$3.75M |
|
|
TWX
60
DELISTED
Time Warner Inc
TWX
| $127M | 0.3% |
1,299,680
+1,374
| +0.1% | +$133K |
|
61
Nike
NKE
$62.5B
| $126M | 0.29% |
2,259,668
+37,670
| +2% | +$2.08M |
|
62
Accenture
ACN
$94.3B
| $123M | 0.29% |
1,025,234
+6,463
| +0.6% | +$772K |
|
63
Lowe's Companies
LOW
$119B
| $123M | 0.29% |
1,490,292
+5,724
| +0.4% | +$438K |
|
|
WBA
64
DELISTED
Walgreens Boots Alliance
WBA
| $122M | 0.29% |
1,470,541
+46,765
| +3% | +$3.92M |
|
65
Colgate-Palmolive
CL
$73.6B
| $122M | 0.28% |
1,666,544
+76,498
| +5% | +$5.35M |
|
66
DuPont de Nemours
DD
$18.9B
| $122M | 0.28% |
756,490
+22,941
| +3% | +$3.56M |
|
|
AGN
67
DELISTED
Allergan plc
AGN
| $120M | 0.28% |
500,793
-25,170
| -5% | -$5.86M |
|
68
United Parcel Service
UPS
$96B
| $117M | 0.27% |
1,091,862
+12,261
| +1% | +$1.34M |
|
69
Mondelez International
MDLZ
$77.9B
| $115M | 0.27% |
2,666,326
+80,331
| +3% | +$3.56M |
|
70
NextEra Energy
NEE
$185B
| $113M | 0.26% |
3,532,644
+276,680
| +8% | +$8.7M |
|
71
NVIDIA
NVDA
$4.76T
| $111M | 0.26% |
40,934,960
+2,181,920
| +6% | +$5.81M |
|
|
DD
72
DELISTED
Du Pont De Nemours E I
DD
| $111M | 0.26% |
1,378,715
+5,323
| +0.4% | +$413K |
|
73
Charter Communications
CHTR
$15.7B
| $110M | 0.26% |
337,309
+4,302
| +1% | +$1.37M |
|
74
Lockheed Martin
LMT
$134B
| $109M | 0.26% |
408,914
+7,124
| +2% | +$1.87M |
|
75
Chubb
CB
$139B
| $109M | 0.25% |
800,594
+57,937
| +8% | +$7.79M |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.